Compare CHWY & BIIB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CHWY | BIIB |
|---|---|---|
| Founded | 2010 | 1978 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Catalog/Specialty Distribution | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 14.2B | 24.2B |
| IPO Year | 2019 | 1991 |
| Metric | CHWY | BIIB |
|---|---|---|
| Price | $33.48 | $181.52 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 23 | 23 |
| Target Price | $45.29 | ★ $176.48 |
| AVG Volume (30 Days) | ★ 6.2M | 1.9M |
| Earning Date | 12-10-2025 | 10-30-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | 0.35 | ★ 10.97 |
| Revenue | ★ $12,345,235,000.00 | $10,065,900,000.00 |
| Revenue This Year | $8.37 | $3.61 |
| Revenue Next Year | $7.82 | N/A |
| P/E Ratio | $95.82 | ★ $16.52 |
| Revenue Growth | ★ 9.17 | 4.77 |
| 52 Week Low | $29.83 | $110.04 |
| 52 Week High | $48.62 | $185.17 |
| Indicator | CHWY | BIIB |
|---|---|---|
| Relative Strength Index (RSI) | 44.82 | 72.92 |
| Support Level | $32.96 | $174.53 |
| Resistance Level | $35.09 | $182.94 |
| Average True Range (ATR) | 1.17 | 5.22 |
| MACD | 0.10 | 0.25 |
| Stochastic Oscillator | 59.11 | 83.54 |
Chewy is the largest e-commerce petcare retailer in the US, generating $11.9 billion in fiscal 2024 sales across pet food, treats, hard goods, and pharmacy categories. The firm was founded in 2011, acquired by PetSmart in 2017, and tapped public markets as a stand-alone company in 2019 after spending a couple of years developing under the aegis of the pet superstore chain. The firm generates sales from pet food, treats, over-the-counter medications, medical prescription fulfillment, and hard goods like crates, leashes, and bowls.
Biogen is an established biopharmaceutical company focused on treatments for neurological diseases and rare diseases. Its declining multiple sclerosis franchise is its largest revenue generator and contributed 45% of total revenue in 2024. Biogen also generates significant revenue from its CD20 collaboration agreements with Roche (18% of total in 2024), which includes oncology drugs Rituxan and Gazyva and multiple sclerosis drug Ocrevus. Biogen's newer franchises include Spinraza (spinal muscular atrophy, with partner Ionis), Leqembi (Alzheimer's disease, collabroation revenue from its partner Eisai), Skyclarys (Friedreich's ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (amyotrophic lateral sclerosis, Ionis).